Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: Results from the Norfolk Arthritis Register

Rheumatology (United Kingdom)

Volumn 55, Issue 9, 2016, Pages 1601-1609

  Cook, Michael J ^a   Diffin, Janet ^a   Scirè, Carlo A ^b   Lunt, Mark ^a   MacGregor, Alex J ^c   Symmons, Deborah P M ^a,d   Verstappen, Suzanne M M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Epidemiology Unit   (Italy)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Disease progression; Inflammatory polyarthritis; Predictors; Remission; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; STEROID; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CLINICAL OUTCOME; COMORBIDITY; DAS28; DEPRESSION; DISABILITY; DISEASE COURSE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; POLYARTHRITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REGISTER; REMISSION; ARTHRITIS, RHEUMATOID; ENGLAND; ONSET AGE;

AGE OF ONSET; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 84995551025     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew210     Document Type: Article

References (48)

1. Ma MH, Scott IC, Kingsley GH, Scott DL. Remission in early rheumatoid arthritis. J Rheumatol 2010;37:1444-53.
2. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
3. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:27-42.
4. Geletka R, St Clair EW. Treatment of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:791-809.
5. Katchamart W, Johnson S, Lin HJ et al. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 2010;62:1128-43.
6. Scirè CA, Verstappen SM, Mirjafari H et al. Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register. Arthritis Care Res 2011;63:945-52.
7. Puolakka K, Kautiainen H, Möttönen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis-five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
8. Lillegraven S, Prince FH, Shadick NA et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012;71:681-6.
9. Verstappen SM. Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol 2015;29:495-511.
10. Möttönen T, Hannonen P, Korpela M et al. Delay to institution of therapy and induction of remission using singledrug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
11. Kuuliala A, Leirisalo-Repo M, Mottonen T et al. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug. Clin Exp Rheumatol 2005;23:243-6.
12. Vázquez I, Graell E, Gratacós J et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol 2007;25:231-8.
13. Hyrich KL, Symmons DP, Watson KD, Silman AJ. British Society for Rheumatology Biologics R. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
14. Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics R. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
15. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3.
16. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Brit J Rheumatol 1994;33:735-9.
17. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Brit J Rheumatol 1986;25:206-9.
18. World Health Organization. International statistical classification of diseases and related health problems, 2009. http://www.who.int/occupational_health/publications/en/oehicd10.pdf] Accessed 19 January 2016.
19. Skogh T, Gustafsson D, Kjellberg M, Husberg M. Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis 2003;62:681-2.
20. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
21. Scirè CA, Lunt M, Marshall T, Symmons DPM, Verstappen SMM. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2014;73:1677-82.
22. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93-9.
23. Smolen JS, Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
24. Aletaha D, Nell VP, Stamm T et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Therapy 2005;7:R796-806.
25. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
26. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
27. de Punder YM, Fransen J, Kievit W et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012;51:1610-7.
28. Thiele K, Huscher D, Bischoff S et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1194-9.
29. Kuriya B, Sun Y, Boire G et al. Remission in early rheumatoid arthritis-a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol 2012;39:1155-8.
30. Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol 2014;41:1607-13.
31. Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL. Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis 2014;73:e74
32. Gossec L, Dougados M, Goupille P et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004;63:675-80.
33. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.
34. Cutolo M, Villaggio B, Craviotto C et al. Sex hormones and rheumatoid arthritis. Autoimmun Rev 2002;1:284-9.
35. Sandberg ME, Bengtsson C, Källberg H et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 2014;73:2029-33.
36. Ajeganova S, Andersson ML, Hafström I, BARFOT Study Group. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 2013;65:78-87.
37. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii. 1-253.
38. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
39. Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metabol 2000;85:3338-42.
40. Kojima M, Kojima T, Suzuki S et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:1018-24.
41. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
42. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain, Behav Immunity 2009;23:936-44.
43. Duivis HE, de Jonge P, Penninx BW et al. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 2011;168:913-20.
44. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiat 2003;54:216-26.
45. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64:1410-3.
46. Forslind K, Hafstrom I, Ahlmen M, Svensson B. Group BS. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007;66:46-52.
47. Burmester GR, Ferraccioli G, Flipo RM et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008;59:32-41.
48. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Obesity in rheumatoid arthritis. Rheumatology 2011;50:450-62.